These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 36450283)
41. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Iketani S; Liu L; Guo Y; Liu L; Chan JF; Huang Y; Wang M; Luo Y; Yu J; Chu H; Chik KK; Yuen TT; Yin MT; Sobieszczyk ME; Huang Y; Yuen KY; Wang HH; Sheng Z; Ho DD Nature; 2022 Apr; 604(7906):553-556. PubMed ID: 35240676 [TBL] [Abstract][Full Text] [Related]
42. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern. Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510 [TBL] [Abstract][Full Text] [Related]
43. In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5. Touret F; Baronti C; Pastorino B; Villarroel PMS; Ninove L; Nougairède A; de Lamballerie X Sci Rep; 2022 Jul; 12(1):12609. PubMed ID: 35871089 [TBL] [Abstract][Full Text] [Related]
44. Antiviral drugs block replication of highly immune-evasive Omicron subvariants ex vivo, but fail to reduce tissue inflammation. Dichtl S; Diem G; Jäger M; Zaderer V; Lupoli G; Dächert C; Muenchhoff M; Graf A; Blum H; Keppler OT; Lass-Flörl C; Weiss G; Wilflingseder D; Posch W Antiviral Res; 2023 May; 213():105581. PubMed ID: 36965526 [TBL] [Abstract][Full Text] [Related]
45. Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period. Fomina DS; Lebedkina MS; Iliukhina AA; Kovyrshina AV; Shelkov AY; Andreev SS; Chernov AA; Dolzhikova IV; Kruglova TS; Andrenova GV; Tukhvatulin AI; Shcheblyakov DV; Karaulov AV; Lysenko MA; Logunov DY; Gintsburg AL Front Immunol; 2023; 14():1259725. PubMed ID: 37928549 [TBL] [Abstract][Full Text] [Related]
46. Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA.2, BA.2.12.1 and BA.5 subvariants dominated era. Sridhara S; Gungor AB; Erol HK; Al-Obaidi M; Zangeneh TT; Bedrick EJ; Ariyamuthu VK; Shetty A; Qannus AA; Mendoza K; Murugapandian S; Gupta G; Tanriover B PLoS One; 2023; 18(4):e0279326. PubMed ID: 37115780 [TBL] [Abstract][Full Text] [Related]
50. Preclinical in vivo assessment of the activity of AZD7442 anti-SARS-CoV-2 monoclonal antibodies against Omicron sublineages. Driouich JS; Cochin M; Lingas G; Luciani L; Baronti C; Bernadin O; Gilles M; Villarroel PMS; Moureau G; Petit PR; Dupont A; Izopet J; Kamar N; Autran B; Paintaud G; Caillard S; le Bourgeois A; Richez C; Couzi L; Xhaard A; Marjanovic Z; Avouac J; Jacquet C; Anglicheau D; Cheminant M; Nguyen S; Terrier B; Gottenberg JE; Besson C; Letrou S; Tine J; Basilua JM; Angoulvant D; Tardivon C; Blancho G; Martin-Blondel G; Yazdanpanah Y; Mentré F; Lévy V; Touret F; Guedj J; de Lamballerie X; Nougairède A Biomed Pharmacother; 2024 Aug; 177():116988. PubMed ID: 38897157 [TBL] [Abstract][Full Text] [Related]
51. Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case. Tatham L; Kipar A; Sharp J; Kijak E; Herriott J; Neary M; Box H; Toledo EG; Valentijn A; Cox H; Pertinez H; Curley P; Arshad U; Rajoli RK; Rannard S; Stewart J; Owen A bioRxiv; 2023 Mar; ():. PubMed ID: 35118468 [TBL] [Abstract][Full Text] [Related]
52. Risk of SARS-CoV-2 infection in patients with hematologic diseases receiving tixagevimab/cilgavimab as pre-exposure prophylaxis in most recent Omicron sublineages era. Vergori A; Cozzi Lepri A; Chiuchiarelli M; Mazzotta V; Metafuni E; Matusali G; Siciliano V; Paulicelli J; Alma E; Siniscalchi A; Sica S; Abruzzese E; Fantoni M; Antinori A; Cingolani A Int J Infect Dis; 2024 Jul; 144():107042. PubMed ID: 38614231 [TBL] [Abstract][Full Text] [Related]
53. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination. Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152 [TBL] [Abstract][Full Text] [Related]
54. Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles. Syed AM; Ciling A; Taha TY; Chen IP; Khalid MM; Sreekumar B; Chen PY; Kumar GR; Suryawanshi R; Silva I; Milbes B; Kojima N; Hess V; Shacreaw M; Lopez L; Brobeck M; Turner F; Spraggon L; Tabata T; Ott M; Doudna JA Proc Natl Acad Sci U S A; 2022 Aug; 119(31):e2200592119. PubMed ID: 35858386 [TBL] [Abstract][Full Text] [Related]
55. Monovalent Omicron COVID-19 vaccine triggers superior neutralizing antibody responses against Omicron subvariants than Delta and Omicron bivalent vaccine. Li W; Zhao T; Tao B; Zhao L; Xiao H; Ding X; Li C; Chen L; Cheng H; Lou Y; Chen Y; Wu C Hum Vaccin Immunother; 2023 Aug; 19(2):2264589. PubMed ID: 37846840 [TBL] [Abstract][Full Text] [Related]
56. Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level. Akerman A; Milogiannakis V; Jean T; Esneau C; Silva MR; Ison T; Fichter C; Lopez JA; Chandra D; Naing Z; Caguicla J; Li D; Walker G; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Foster CSP; Sato K; Lee S; Song Y; Mao L; Sigmund A; Phu A; Vande More AM; Hunt S; Douglas M; Caterson I; Britton W; Sandgren K; Bull R; Lloyd A; Triccas J; Tangye S; Bartlett NW; Darley D; Matthews G; Stark DJ; Petoumenos K; Rawlinson WD; Murrell B; Brilot F; Cunningham AL; Kelleher AD; Aggarwal A; Turville SG EBioMedicine; 2023 Apr; 90():104545. PubMed ID: 37002990 [TBL] [Abstract][Full Text] [Related]
57. Structural Insight into the Resistance of the SARS-CoV-2 Omicron BA.4 and BA.5 Variants to Cilgavimab. Fujita S; Kosugi Y; Kimura I; Yamasoba D; The Genotype To Phenotype Japan G P-Japan Consortium ; Sato K Viruses; 2022 Nov; 14(12):. PubMed ID: 36560681 [TBL] [Abstract][Full Text] [Related]
58. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2. Qu P; Evans JP; Faraone JN; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Xu K; Gumina RJ; Liu SL Cell Host Microbe; 2023 Jan; 31(1):9-17.e3. PubMed ID: 36476380 [TBL] [Abstract][Full Text] [Related]
59. Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection. Zhu KL; Jiang XL; Zhan BD; Wang XJ; Xia X; Cao GP; Sun WK; Huang PX; Zhang JZ; Gao YL; Dai EH; Gao HX; Ma MJ Cell Rep; 2023 Feb; 42(2):112075. PubMed ID: 36774551 [TBL] [Abstract][Full Text] [Related]
60. Clinical efficacy of anti-SARS-CoV-2 monoclonal antibodies in preventing hospitalisation and mortality among patients infected with Omicron variants: A systematic review and meta-analysis. Miljanovic D; Cirkovic A; Lazarevic I; Knezevic A; Cupic M; Banko A Rev Med Virol; 2023 Jul; 33(4):e2439. PubMed ID: 36924087 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]